Your Global Leader in Stem Cell Market Research
Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits.
In this article:
Miami, FL (August 6, 2020) — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) approved two outpatient Emergency Investigational New Drug Applications (eINDs) for treating mild to moderate respiratory distress due to COVID-19. [Read more…]
Extracellular vesicles (EVs) are known for their role in facilitating wide range of intercellular communication such as regulation of the immune response and stem cells differentiation.
EVs are membrane-enclosed particles ranging in size from 30nm to 300nm and their characteristic depend on the cell type releasing them. Often they will carry cargo of active molecules like RNA, DNA, proteins, metabolites and lipids. Moreover, EVs can be found in most biological fluids with the ability to cross biological barriers, and in the case of pathological conditions, the composition of the cargo will be distinctive to the disease. Altogether, these features have led to intense research into the potential role of EVs for diagnostics, biomarkers and as vehicles for drug delivery. [Read more…]
Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells.
In recent years, exosomes have gained attention as a strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering the cells to patients.
With at least 13,703 scientific articles published about exosomes and 169 clinical trials underway, these small vesicles have intriguing potential to be used within a range of therapeutic applications. [Read more…]
MELBOURNE, Australia – Jan. 29, 2020 11:00 UTC — Regenerative medicine company Exopharm Limited (ASX:EX1) announces first dosing has occurred in the PLEXOVAL Phase I study using exosomes isolated from human platelets for wound healing, Exopharm’s first human clinical trial. Further participants are expected to soon follow in this study that involves up to 20 participants. [Read more…]
